中美仿制药研发申报流程.精讲.ppt

《中美仿制药研发申报流程.精讲.ppt》由会员分享，可在线阅读，更多相关《中美仿制药研发申报流程.精讲.ppt（59页珍藏版）》请在淘文阁 - 分享文档赚钱的网站上搜索。

1、中美仿制药研发和申报流程涂家生，Ph.D.中国药科大学药剂学教授Tel:025-83271305Email:2011.11 郑州我国仿制药申报、审评和研发我国仿制药申报、审评和研发对策对策主要内容主要内容中美关于原研药和仿制药的背景中美关于原研药和仿制药的背景美国仿制药：申报、基于问题的美国仿制药：申报、基于问题的审评和研发对策审评和研发对策展望展望1 12 23 34 4药物经济学催生美国仿制药制度药物经济学催生美国仿制药制度美国社会安全制度导致政府赤字严重美国社会安全制度导致政府赤字严重SSA已经破产：如何破局？已经破产：如何破局？降低医疗费用成为必然降低医疗费用成为必然Hatch-Wax

2、man法案出台法案出台美国美国FDA药品注册申请：新药（两类）、仿制药和药品注册申请：新药（两类）、仿制药和非处方药申请非处方药申请3Ceryak1984年后年后New Drug Applications(NDAs)Abbreviated New Drug Applications(ANDAs)“Full Reports”of Safety and Efficacy Investigations Applicant has right of reference to essential investigations?Duplicate of an already approved produc

3、t No safety/efficacy data permitted(only bioequivalence)YESNO505(b)(1)505(b)(2)505(j)NDA的研发和申报的研发和申报505(b)(1)新药申报资料内容新药申报资料内容1.Index2.Summary3.Chemistry,Manufacturing and Control4.Samples,Methods Validation Package and Labeling5.Nonclinical Pharmacology and Toxicology6.Human Pharmacokinetics and Bio

4、availability7.Microbiology(for anti-microbial drugs only)8.Clinical Data9.Safety Update report(typically submitted 120 days after the NDAs submission)10.Statistical11.Case Report Tabulations12.Case Report Forms13.Patent Information14.Patent Certification505(b)(2):历史过程历史过程vHatch Waxman法案：法案：1984vPark

5、man LetterPhantom ANDAvFDA Draft Guidance for Industry(1999)vFDA Response to Citizens Petition(2003)v可以降低研发的费用和审评力量的浪费可以降低研发的费用和审评力量的浪费505(b)(2)的关键的关键:可靠性可靠性vWhat is“Reliance”By whom?On what?vReliance and ExclusivityMarket vs.Data ExclusivitySafety/Efficacy Data vs.CM&C datavFDA Process for Determin

6、ing RelianceWho,when and how?505(b)(2)的意义的意义v介于全创新药物和仿制药之间介于全创新药物和仿制药之间v具有专利保护，且不存在产权纠纷具有专利保护，且不存在产权纠纷v和仿制药不同，无替换的要求和仿制药不同，无替换的要求 v应有突破应有突破505(b)(2)范围范围vNew Chemical Entity(rarely)：我：我国国1.1-1.3vNew dosage form：我国：我国5类类vNew dosing regimen：我国补充申：我国补充申请请vNew strength：我国补充申请：我国补充申请vNew route of administ

7、ration：我：我国国2类类vNew indication：我国：我国1.6505(b)(2)情形情形vNew active ingredient(different salt,ester,complex,chelate,clathrate,racemate,or enantiomer of active moiety)vNew inactive ingredient that requires more than limited confirmatory studiesvRx OTC switchvNew Combination Productsv“Generic biologics”50

8、5(b)(2)排他性排他性Exclusivities available for 505(b)(2)productsNCE Exclusivity(5 years)New Product Exclusivity(3 years)Orphan Drug Exclusivity(7 years)Pediatric exclusivity extensions(6 months)Patent Issues505(b)(2)drugs can have Orange Book-listed patents,and enjoy 30-month stay protection against gener

9、ic competitorsBut,505(b)(2)NDAs may also be blocked by patents on Reference Drugs505(b)(2)新药的成功例子新药的成功例子vNCEThalomid(thalidomide)(1998)vMarketed unapproved drugsLevothyroxine(2000)Guaifenesin extended release(2002)Quinine sulfate(2005)vNew Dosage FormTramadol orally disintegrating tablets(2005)Ondan

10、setron oral spray(filed 2006)505(b)(2)新药的例子新药的例子vNew Dosing RegimenTramadol extended release tablets(2005)vNew Strength/FormulationAntara(micronized fenofibrate caps)(2004)(130 mg is BE to Tricor 200 mg)vNew Formulation/Inactive IngredientAvita(tretinoin gel)(new emollient)(1998)Abraxane(cremaphor-f

11、ree paclitaxel)(2005)Oxy-ADF(oxycodone formulated to reduce drug abuse)(in development)505(b)(2)新药的例子新药的例子vNew Active IngredientPexeva(paroxetine mesylate)(new salt)(2003)vNew Route of AdministrationEmezine(prochlorperazine)(new buccal/transmucosal delivery)(NDA pending)Oral amphotericin-B(pre-clini

12、cal)vRxOTC SwitchAlavert(loratadine)(2002)505(b)(2)新药的例子新药的例子v“Generic Biologics”Omnitrope(rHGH)(2006)Glucagen(glucagon recombinant)(1998)Hyaluronidase(various approvals 2004-05)Fortical(calcitonin salmon recombinant)(2005)*Examples based on publicly available informationFDA NDA 审评审评过程过程FDA 可以使用已有数据

13、用于审评可以使用已有数据用于审评NDA吗？吗？vHatch-Waxman之前之前,国会限制国会限制 FDA在审评在审评 NDA X时应时应用用 NDA Y的数据：的数据：“No data in an NDA can be utilized to support another NDA without express permission of the original NDA holder.”FDA“Finkel Memorandum”(1978,1981)vHatch-Waxman 解除只适合解除只适合 ANDAs：ANDA process allows“generic producer o

14、f the fully tested drug to rely on the safety and efficacy data of a prior applicant.”v505(b)(2)does not authorize such data relianceMerely sets conditions for certain NDAsRequires“full reports of investigations”establishing safety and effectiveness 21 USC 355(b)(1)(A),(d)(1)美国仿制药 A generic drug pro

15、duct is one that is comparable to an innovator drug product(also known as the reference listed drug(RLD)product as identified in the FDAs list of Approved Drug Products with Therapeutic Equivalence Evaluations)in dosage form,strength,route of administration,quality,performance characteristics and in

16、tended use.Generic drug applications are termed“abbreviated”in that they are generally not required to include preclinical(animal)and clinical(human)data to establish safety and effectiveness.These parameters were established upon the approval of the innovator drug product,which is the first version

17、 of the drug product approved by the FDA.FDA审评仿制药程序二、美国仿制药的申报、审评和研发对策二、美国仿制药的申报、审评和研发对策v由由FDA的的OGD审评审评v审评方式采用审评方式采用QbRv申报资料采用申报资料采用CTDv资料内容也针对问题资料内容也针对问题Office of Generic Drugs如何保证审评质量和效率？如何保证审评质量和效率？vStructured Product Labeling(SPL)Makes labeling available on Internet via National Library of Medici

18、ne(NLM)vReview EfficienciesEarly DMF reviewCluster reviews product specialistsSupplement triaging at team leader levelDBE Truncated ReviewvQuestion based Review(QbR)Will have a very positive impactvNew resources developedDissolution DatabaseIndividual Product Bioequivalence InformationvEncouraged th

19、e use of telephone in review processIncreased the number of 1st cycle approvalsDecreased the total number of review cyclesTotal time to approval did not increase in spite of increased workload Dissolution Methods for Drug ProductsNew!benThis guidance contains an Internet link to a listing of drug pr

20、oducts,each linked in turn to a corresponding bioequivalence recommendation.Clicking on a product name in that list will bring up the bioequivalence recommendations for that specific product.Recommendations have been developed for several drugs that are not yet eligible for generic competition(i.e.,

21、newly approved products)and some older products for which information has previously been provided.As additional recommendations are developed,those will be posted on the Web site.When this guidance is finalized,the listing will be available through the Agencys Web page.OFFICE OF GENERIC DRUGSTABLE

22、OF BIOEQUIVALENCE RECOMMENDATIONSActive IngredientPotencyDosage FormRoute of AdministrationDate FinalizedAlmotriptan Malate12.5 mgTabletOral5/16/2005Alosetron1 mgTabletOral5/31/2005Atazanavir200 mgCapsuleOral3/18/2005Atomoxetine60 mgCapsuleOral6/13/2005Cefditoren Pivoxil200 mgTabletOral3/18/2005Duta

23、steride0.5 mgCapsuleOral7/5/2005Eplerenone50 mgTabletOral3/18/2005Fosamprenavir Calcium700 mgTabletOral3/18/2005Memantine10 mgTabletOral7/8/2005Rosuvastatin40 mgTabletOral3/18/2005Tadalafil20 mgTabletOral3/18/2005Vardenafil HCl20 mgTabletOral4/11/2005QbR:从提出到完善从提出到完善1/2005 2/2005:Question-based Revi

24、ew Drafted3/2005 4/2005:Division Directors Discussion5/2005 6/2005:Team Leaders Discussion7/2005 8/2005:Reviewers Discussion9/2005 1/2006:Model Pharmaceutical Development Report and Quality Overall Summary2/2005 12/2005:Discussions with Stakeholders and Upper Management1/2005 12/2006:Gradual Impleme

25、ntation1/2007:Full ImplementationQbR的内涵的内涵vQuestion-based Review is a general framework for a science and risk-based assessment of product qualityvQuestion-based Review contains the important scientific and regulatory review questions to关键制备工艺及其质控产品的工艺、处方是否有设计缺陷强调QbDANDAs Under QbR(Continued)vFuture

26、 Generic Applications generic sponsors submit generic applications based on the format of ICH CTD,preferably,electronicallyModule 1:Administrative InformationModule 2:Quality Overall Summary and Clinical SummaryModule 3:QualityPharmaceutical Development;Quality by DesignModule 4:NonclinicalModule 5:

27、Clinical(Bioequivalence)新药申报（新药申报（NDA）和仿制药申报（和仿制药申报（ANDA）的比较）的比较1.Chemistry2.Manufacturing3.Controls4.Labeling5.Testing6.Animal Studies7.Clinical Studies8.BioavailabilityNDA requirementsANDA requirements1.Chemistry2.Manufacturing3.Controls4.Labeling5.Testing6.Bioequivalence美国仿制药申报美国仿制药申报模块模块1 1包含了管理

28、和处方信息，这个是区域特异的。在美国应包括以下信息：申请书3674；专利认证信息；原研药信息，包括NDA号、药名和生产商；仿制药和原研药的对比，包括使用条件、有效成分、非有效成分、给药途径、剂型和剂量；环境影响分析；药品说明书（草稿）。模块模块2 2模块2为概论。它包括药理作用分类，作用模式以及临床适应证。模块模块3 3应该包含原料药和制剂相关的化学、生产和质量控制信息。FDA仿制药部（OGD）鼓励申请人根据ICH对于人用药物的注册技术要求，即通用技术文件（CTD）的格式，提交ADNA。包括以下模块：模块模块4 4模块4是关于动物实验的信息，并不是ANDA要求的。所以，仿制药申请一般不包含模块

29、4。模块模块5 5模块5是临床研究报告。对于ADNA，生物等效性信息应该在这个部分体现，包括：生物等效性研究；体外体内相关性研究；生物分析方法开发。案例报告，包括不良反应事件报告也应包括在此。LOGO OGD QBR The question based review(QBR)serves as a general framework for the CMC assessment of ANDAs that focuses on critical pharmaceutical attributes of product quality.With justification,deviations

30、 or alternate approaches to this framework can be utilize,as necessary,to ensure the adequacy of the assessment of product qualityFor ease of discussion,a simple dosage form is defined as a solution or an immediate release(IR)solid oral dosage form.QBR:Drug SubstancevDescription and Characterization

31、What are the nomenclature,molecular structure,molecular formula,and molecular weight?What are the pKa,aqueous solubility(as function of pH),partition coefficient,polymorphism,hygroscopicity,and melting points?vControl of Drug SubstanceAppearance and IdentificationAre the specifications for appearanc

32、e and identification appropriate?AssayIs the proposed drug substance assay limit acceptable?Is the analytical method validated and stability-indicating?Impurities and Residual SolventsAre all the possible impurities accounted for?What is the justification for the impurity acceptance limits?Are the a

33、nalytical methods validated and suitable for their intended function?Additional SpecificationsBased on the review of the drug product and manufacturing process are specification(s)required on particle size,solid state form,moisture content,or other properties of the drug substance and why?For each a

34、dditional specification:What is the justification for the acceptance limit?Is it suitable for its intended function?QBR:Drug ProductvDescription and Composition What are the components and composition of the final product?What is the function of each excipient?Do any excipients exceed IIG limits in

35、the context of maximum daily dose and route of administration?If product is an NTI drug or a non-simple dosage formAre there significant differences between this formulation and the RLD that present potential concerns with respect to product performance?vControl of ExcipientsWhat are the specificati

36、ons for the inactive ingredients and are they appropriate per their intended function?Simple Dosage Form:Either a solution or an IR solid oral dosage formQBR:Drug Product(Continued)vManufactureFor all productsDoes the batch formula accurately reflect the drug product composition?If not,what are the

37、differences and the justifications(e.g.potency adjustment,overage,excess coating solution,etc.)?If product is not a solution What are the key unit operations in the drug product manufacturing process?Are in-process tests identified by the sponsor appropriate?What is the difference in size between co

38、mmercial scale and biobatch and do they use the same unit operations?If product is an NTI drug or a non-simple dosage formWhat are the critical steps in the manufacturing process?What are the in-process tests/controls that ensure each critical step is successful?In the proposed scale up process what

39、 operating conditions will be adjusted to ensure the product meets all in-process and final product specifications?Why do you believe the sponsor has demonstrated a reasonable plan to scale up the process?QBR:Drug Product(Continued)vControl of Drug ProductIdentityIs the specification for the identit

40、y of the drug product appropriate?Assay and UniformityAre the proposed drug assay limits acceptable?Is the assay method validated and stability-indicating?How is the content uniformity evaluated?Is it acceptable?Impurities/Degradation ProductsAre the degradation products and their origins adequately

41、 described?What is the justification for the acceptance limits on degradation products?Are the analytical methods validated and suitable for their intended function?Dissolution What are the dissolution methods and acceptance criteria and how were they selected?What is the significant role of dissolu

42、tion testing for this product?Additional SpecificationsAre there additional specifications that are required to ensure the product will perform as labeled and why?For each additional specification:What is the justification for the acceptance limit?Are the analytical methods validated and suitable fo

43、r their intended function?QBR:Drug Product(Continued)vReference StandardAre there a qualification report and COA provided for the reference standard or is this material purchased from an appropriate source?vContainer/Closure System Has the container/closure system been used in a previously approved

44、product or otherwise qualified for this dosage form?What specific container/closure attributes are necessary to ensure product performance?vDrug Product StabilityDataWhat stability data has been submitted?Has the sponsor provided stability data for the drug product packaged in the proposed container

45、/closure?Acceptance limitsAre all attributes that could change over time evaluated in the stability tests?What are the acceptable limits on these attributes?Shelf-life recommendationWhat is the justification of shelf life?Is the post-approval stability protocol acceptable?QBR:Product Development Rep

46、ort for Complex Dosage Forms and NTI DrugsvDrug Substance Which properties or physical chemical characteristics of the drug substance affect drug product performance?vExcipients Is there any evidence of incompatibility between the excipients and drug substance?vFormulation What is the formulation in

47、tended to do?What mechanism does it use to accomplish this?Were any other formulation alternatives investigated and how did these perform?Were any formulation optimization or sensitivity studies carried out for variations in composition around the final formulation?Were these studies sufficient to e

48、stablish a design space for formulation composition?Is the formulation design consistent with the dosage form classification in the label?vDrug ProductWhat are the critical quality attributes that ensure the product will perform as labeled?QBR:Process Development ReportvProcess DescriptionWhy was th

49、is manufacturing process selected for this drug product?Were alternative unit operations investigated by process development studies?vCritical Steps and Scale UpHow were the critical steps in the process identified?What are the critical process parameters for each critical step and how were they ide

50、ntified,monitored and/or controlled?Were process development studies that varied starting materials or operating parameters conducted?Were these studies sufficient to establish a design space for process?In process testsWhy is each in process test required?How were the acceptance limits chosen?Why w